What caused the MAAT.PA stock jump today?

The intraday jump to **€6.66** was driven by increased trading volume and renewed interest in clinical updates. High relative volume **191,519** shares and biotech sector momentum pushed MAAT.PA higher on EURONEXT.

What is Meyka AI's forecast for MAAT.PA stock?

Meyka AI's forecast model projects a yearly price of **€1.55**, which implies an estimated downside of **-76.71%** versus the current **€6.66**. Forecasts are model-based projections and not guarantees.

How does MAAT.PA stock rate by Meyka AI?

Meyka AI rates MAAT.PA with a score of **62.10 out of 100** (Grade: **B**, Suggestion: **HOLD**). This factors in benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

What key metrics should investors watch for MAAT.PA stock?

Monitor trial readouts, cash runway, EPS **-€2.15**, market cap **€92.50m**, and volume relative to average. Watch resistance at **€8.28** and support near the 50-day average of **€4.52**.

EU Stocks

MAAT.PA MaaT Pharma EURONEXT 27 Jan 2026 up 19.35%: short-term test of €8.28 possible

ByDanny Kontos January 27, 2026

MAAT.PA stock surged intraday on 27 Jan 2026 to €6.66, a +19.35% move from yesterday’s close of €5.58. Volume jumped to 191,519 shares, about 4.21x average, making MaaT Pharma SA (MAAT.PA) one of today’s top gainers on EURONEXT in Europe. The rally follows mixed clinical updates and active trading interest in the biotechnology sector. We examine what drove the spike, how fundamentals and technicals align, and where the stock could head next.